71.4 F
New York
Friday, October 15, 2021

Regeneron’s [NASDAQ: REGN] REGEN-COV Shows Promising Results in Hospitalized COVID-19 Patients

Must read

Turquoise Hill [NYSE: TRQ] Shares Oyu Tolgoi Mine Update

Turquoise Hill Resources Ltd. disclosed Q3 2021 production for Oyu Tolgoi LLC (Oyu Tolgoi) and shared an update on the Oyu Tolgoi mine....

Amazon’s [NASDAQ: AMZN] AWS Chosen by NXP as Preferred Cloud Provider

Amazon.com, Inc. disclosed that NXP Semiconductor has chosen AWS as its preferred cloud provider. NXP has decided to shift the broad majority of...

Accenture [NYSE: ACN] Announces Acquisition of BRIDGEi2i

Accenture plc disclosed that it has inked an agreement to purchase BRIDGEi2i which is an artificial intelligence (AI) and analytics firm based in...

Rio Tinto’s [NYSE: RIO] Perth Airport Vaccination Clinics Begins for Mining Industry

Rio Tinto Group has disclosed that its vaccination hub at Perth Airport has started COVID-19 vaccination for the workers of the mining industry. ...

Regeneron Pharmaceuticals, Inc. [NASDAQ: REGN] disclosed that REGEN-COV which is the combination of casirivimab and imdevimab has demonstrated promising results in hospitalized COVID-19 sufferers. These new promising outcomes, along with the nearly 10,000-patient RECOVERY study, further confirm how REGEN-COV can change the course of illness for sufferers even after they are hospitalized with COVID-19.

The trial has achieved the primary endpoints which is the greatest accomplishment of the firm. The firm is continuously striving to end the suffering of people after the pandemic has wreaked havoc all around the globe. The outcomes of the study will be demonstrated at IDWeek 2021 today. The outcomes will demonstrate that REGEN-COV has the capacity to decrease viral load in sufferers hospitalized with COVID-19.

Furthermore, the study was halted because of the slow registration after enlisting just over one-third of the patients originally decided. The study has discovered that victims who got REGEN-COV plus standard-of-care (SOC) experienced numeric improvements across all clinical endpoints evaluated.

In addition, REGEN-COV is an investigational medicine approved by the U.S. FDA. It has got an emergency use approval to cure people who are at high risk of serious results from COVID-19 infection who are either already infected or in certain post-exposure prophylaxis settings.

More articles

Latest article

21Shares Lists 5 Additional Crypto ETPs on Euronext Paris and Amsterdam

21Shares which has earned a reputation as the world’s largest issuer of cryptocurrency ETPs has disclosed that it has listed 5 additional ETPs in...

Electronic Arts [NASDAQ: EA] Share its Clear Vision for the Future of Football

Electronic Arts Inc. has disclosed a record-breaking FIFA 22 launch and also shared its stance on the future of football. EA has talked...

Bitcoin, Ethereum Gain All-Time High as SEC Confirms no Plan To Ban Cryptocurrency

Bitcoin, Ethereum, Dogecoin traded all-time high after the U.S. SEC Chair Gary Gensler disclosed that HEC is not considering the China-like cryptocurrency ban policy...

KuCoin Cryptocurrency Exchange Decides Not to Offer Services to Mainland China Customer

Cryptocurrency exchange KuCoin has decided to respond to the crackdown of Chinese authorities. The firm has disclosed that the customer in Mainland China will...

Bitcoin Firm Bitfarms [NASDAQ: BITF] Decides to Expand Québec Mining Operations

Bitcoin mining Bitfarms Ltd. disclosed that it has decided to increase its corporate hash rate to more than 1.6 Exahash per second (EH/s)....

KKR [NYSE: KKR] Announces Acquisition of Probe CX

KKR & Co. Inc. disclosed that it has inked an acquisition agreement with Quadrant Private Equity, Five V Capital, Rodney Kagan, and other...

Regeneron’s [NASDAQ: REGN] REGEN-COV Shows Promising Results in Hospitalized COVID-19 Patients

Regeneron Pharmaceuticals, Inc. disclosed that REGEN-COV which is the combination of casirivimab and imdevimab has demonstrated promising results in hospitalized COVID-19 sufferers. These...

Huntsman [NYSE: HUN] and KPX Chemical Establish Joint Venture in Korea

Huntsman Corporation has disclosed that it has joined forces with KPX Chemical to launch a joint venture (JV) in Korea. The joint venture...